Hepatitis B Virus (HBV) DNA, Quantitative, Real-Time PCR

The Hepatitis B Virus (HBV) DNA, Quantitative, Real-Time PCR test—often referred to as HBV viral load—assesses the level of viral replication and overall disease activity. It helps corroborate chronic HBV infection and carrier status, detect occult or mutant strains, and serves as an objective metric to initiate and follow antiviral treatment. Serial HBV DNA quantitation by real-time PCR is used to evaluate treatment response over time, enabling clinicians to track trends, document suppression, and identify suboptimal response during antiviral therapy.

Hepatitis B is a DNA virus transmitted through blood and other body fluids, with sexual, parenteral, and perinatal routes of exposure. Clinical manifestations range from asymptomatic or mild acute hepatitis to chronic infection that carries risks for cirrhosis and hepatocellular carcinoma. Laboratory evaluation combines serologic markers (HBV antigens and antibodies) with nucleic acid testing for HBV DNA. Real-time PCR offers high analytical sensitivity and specificity and can be performed in qualitative or quantitative formats. Quantitative HBV DNA reflects viral replication, aligns with biochemical and serologic indicators such as HBeAg and ALT, and is associated with the likelihood of disease progression. During effective antiviral therapy, HBV DNA typically falls by approximately 1–2 log10 within 3–6 months; absence of this decline or a rising level suggests inadequate response or possible antiviral resistance and should prompt reassessment of the regimen.